Limitations and Challenges in Mapping Ventricular Tachycardia: New Technologies and Future Directions by Graham, AJ et al.
Limitations in Mapping Ventricular Tachycardia
118 ©  R A D C L I F F E  C A R D I O L O G Y  2 0 1 7
Clinical Arrhythmias
Access at: www.AERjournal.com
Recurrent episodes of ventricular tachycardia (VT) in patients with 
structural heart disease are associated with increased mortality and 
morbidity, despite the life-saving benefits of implantable cardiac 
defibrillators (ICDs).1,2 Because ICD therapies are abortive and do 
not alter the underlying arrhythmogenic substrate, their reduction 
becomes important, especially as recurrent shocks can cause 
increased myocardial damage and stunning, despite the conversion of 
VT/VF.3,4 Antiarrhythmic drugs can reduce the number of ICD therapies, 
but their long-term use is hindered by side-effects, especially with the 
most effective agent, amiodarone.5 In the absence of revolutionary 
drugs or antifibrotic regenerative therapies, catheter ablation has 
emerged as a potential therapeutic option either for primary or 
secondary prevention of these arrhythmias. This is particularly relevant 
to post-MI cases where the substrate is well defined. However, the 
outcomes of catheter ablation of VT in structural heart disease 
remain unsatisfactory in comparison with other electrophysiological 
procedures; initial first time success rates are only 50–70 % in most 
large series versus 80–90  % in normal heart VT.6 The disappointing 
efficacy of VT ablation in structural heart disease is multifactorial, 
relating to both our inability to fully delineate the substrate’s 
fixed and functional electrophysiology determining VT initiation and 
maintenance, as well as the delivery of adequate lesion sets to the 
critical arrhythmogenic sites. 
Mapping during VT
There have been rapid advances in the field of ventricular arrhythmia 
therapy over the past two decades following the seminal studies 
characterising post-infarction VT substrates during cardiac surgery.7–10 
Activation mapping is now utilised to locate the point of the earliest 
activation of tachycardia, with entrainment subsequently performed 
to not only confirm re-entry as the arrhythmia mechanism but to 
allow for accurate delineation of the critical components of a circuit.11 
The main target for ablation being the central isthmus, represented by 
mid-diastolic potentials during VT and specific entrainment criteria. 12 The 
entrainment of VT in the right ventricle of a patient with arrhythmogenic 
right ventricular cardiomyopathy is illustrated in Figure 1.
Electro-anatomical mapping and advances in catheter technology have 
made VT ablation procedures routine in tertiary centres, particularly 
in post-infarction VT where arrhythmias are more amenable to 
these activation and entrainment mapping strategies. Indeed, 
elegant mechanistic studies have identified the role of border zone 
ultrastructure, scar geometry and anisotropy in determining wavefront 
curvature and functional block critical to initiate re-entry.13 Ciaccio 
et al. showed that infarct scar geometric features can be utilised 
to localise VT isthmuses, and sites of slow stable conduction lie in 
close proximity to sites of functional block.14 These principles have 
been applied clinically in post-infarction VT and recently utilised to 
define pro-arrhythmic areas based on electrogram morphology and 
stability; for example, Shannon entropy.15,16 However, in non-ischaemic 
cardiomyopathy, specific features of the substrate (e.g., myocyte 
disarray promoting anisotropy in hypertrophic cardiomyopathy or 
disruption of myocyte electro-mechanical coupling by desmosomal 
mutations in arrhythmogenic cardiomyopathy) create functional 
changes in the tissue to promote conduction block and re-entry. 
Furthermore, the scar is often very diffuse, making simple delineation 
of border zones seen in post-infarction VT challenging to define for 
substrate modification in these disorders.
Abstract
Recurrent episodes of ventricular tachycardia in patients with structural heart disease are associated with increased mortality and 
morbidity, despite the life-saving benefits of implantable cardiac defibrillators. Reducing implantable cardiac defibrillator therapies is 
important, as recurrent shocks can cause increased myocardial damage and stunning, despite the conversion of ventricular tachycardia/
ventricular fibrillation. Catheter ablation has emerged as a potential therapeutic option either for primary or secondary prevention of these 
arrhythmias, particularly in post-myocardial infarction cases where the substrate is well defined. However, the outcomes of catheter ablation 
of ventricular tachycardia in structural heart disease remain unsatisfactory in comparison with other electrophysiological procedures. The 
disappointing efficacy of ventricular tachycardia ablation in structural heart disease is multifactorial. In this review, we discuss the issues 
surrounding this and examine the limitations of current mapping approaches, as well as newer technologies that might help address them.
Keywords
Ventricular tachycardia, substrate mapping, arrhythmia, cardiomyopathy, catheters, ripple mapping
Disclosure: Pier D Lambiase receives speaker fees, educational grants and research grants from Medtronic and Boston Scientific.
Received: 21 July 2017 Accepted: 15 August 2017 Citation: Arrhythmia & Electrophysiology Review 2017;6(3):118–24. DOI: 10.15420/aer.2017.20.1
Correspondence: Adam Graham, Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London, EC1A 7BE, UK.  
E: Adam.graham@bartshealth.nhs.uk
Limitations and Challenges in Mapping Ventricular Tachycardia: New 
Technologies and Future Directions
Adam J Graham,1 Michele Orini1,2 and Pier D Lambiase1,2
1. Barts Heart Centre, London; 2. Institute of Cardiovascular Science, UCL, London, United Kingdom
AER_Lambiase_FINAL.indd   118 22/08/2017   23:17
A R R H Y T H M I A  &  E L E C T R O P H Y S I O L O G Y  R E V I E W 119
Limitations in Mapping Ventricular TachycardiaClinical Arrhythmias
 Therefore, functional changes independent of fibrosis might play an 
important role in ventricular arrhythmogenesis. This means that ablation 
relying on identifying fibrotic regions as potential VT isthmuses is 
probably inadequate, especially since it is assumed that the mechanism 
of VT involves a critical isthmus, but it is also possible that micro 
re-entry in an adjacent site is the primary driver with a bystander 
isthmus.17 Such sites will elude conventional ablation catheter bipolar 
mapping due to lack of resolution, but could be defined in tachycardia 
with higher-density mapping catheters (e.g., PentaRay or Orion basket); 
the functional and structural features of these sites can be dissected. 
This would explain the lower success rates of ablation in dilated 
cardiomyopathy versus post-MI VT, as the mechanism has not been 
defined or the circuit eludes conventional ablation catheter mapping.18–20
Therefore, despite our ability to identify post-MI VT isthmuses with a 
view to ablation in stable circuits, there remain significant knowledge 
gaps in predicting the probability of VT and their anatomical location in 
individual cases, especially non-ischaemic cardiomyopathies, and the 
planning of the substrate modification required.
As a result, extensive endo-epicardial ablation and ‘scar 
homogenis ation’ are frequently performed to modify potentially-
arrhythmogenic sites with limited functional analysis.21 This risks 
unnecessary myocardial damage and pro-arrhythmia.22 Furthermore, 
in cardiomyopathy patients, diffuse areas of epicardial fibrosis act as 
potential re-entry sites, but the arrhythmias are often unmappable 
because they are haemodynamically unstable or not sustained.23 A 
deeper understanding of mechanisms of VT in these cases (i.e., micro 
re-entry, functional block leading to isthmus formation, repetitive 
Purkinje activity, the interplay between structural inhomogeneities 
and dynamic conduction–repolarisation interactions) is required to 
optimise therapeutic targeting and risk stratification in VT.
A major limitation of mapping during VT is haemodynamic intolerance 
of the arrhythmia, with as few as 10  % of arrhythmias induced 
being stable.24 Advances in interventional cardiology have led to 
smaller infarct sizes and VTs with shorter cycle lengths accounting 
for the decreasing use of mapping during tachycardia due to their 
haemodynamic instability or transient nature.25 The obstacle posed 
by unstable VTs could be addressed using haemodynamic support 
devices. Percutaneous left ventricular assist devices allow more 
detailed and prolonged mapping of unstable VTs, with more VTs 
terminated by ablation, although no impact on the inducibility of VT 
at the end of procedures is evident.26 Whether these disappointing 
results are due to selection bias needs to be analysed in further 
trails.27 Extracorporeal membrane oxygenation has also been studied 
in this context. Its use allows for mapping, ablation and subsequent 
non-inducibility of VTs that were previously inducible at the end 
of substrate-based approaches. In this study, the acute procedural 
success, in terms of non-inducibility, was associated with better long-
term outcomes. The approach had low complication rates and could 
be increasingly utilised in the future.28 However, prospective studies are 
lacking and will be necessary for rigorous evaluation of the technique.
On a practical level, although entrainment mapping is seen by many 
as the gold standard for the interrogation of a re-entrant circuit, it 
also suffers limitations that stretch beyond the afore-mentioned 
haemodynamic issues. Problems include inability to capture or having 
to increase pacing outputs, which increase the volume of captured 
tissue leading to inaccuracies in defining the exact site of the isthmus, 
as the captured area can be over 2 cm away. Even if consistent capture 
is achieved, oscillations in the tachycardia cycle length can introduce 
errors, resulting in misleading post-pacing intervals or local tissue 
properties causing latency and long return cycle lengths, appearing 
as bystander sites. These confounding issues might only become 
apparent after ablation has not terminated the tachycardia. Finally, 
due to the muscular bundles that form the isthmus being only a few 
hundred microns in diameter, the diastolic component can be very low 
in amplitude and difficult to detect, especially if the noise levels in the 
catheter laboratory are high and mapping system filters saturated at 
specific frequencies.29
Substrate Mapping
Due to these limitations, and the fact that patients can have multiple 
haemodynamically unstable or non-sustained VT, substrate mapping 
and ablation have gained popularity. During sinus rhythm mapping, 
low-amplitude, fractionated electrograms and late potentials associated 
with surviving bundles of myocardial tissue surrounded by fibrous 
There is acceleration of the tachycardia to the paced cycle length 20 ms faster than the TCL. 
Morphology of the paced QRS complexes is identical to the VT surface QRS morphology; this 
represents entrainment with concealed fusion. Post-pacing interval is 4 ms shorter than the 
TCL, and there is a mid-diastolic potential evident on the ablation catheter signal. Stim–QRS 
interval is identical to the mid-diastolic potential–QRS time (244 ms), indicating that pacing is 
occurring mid-cycle, consistent with pacing in the centre of the VT circuit isthmus.  
IHD = ischaemic heart disease; TCL = tachycardia cycle length; VT = ventricular tachycardia.
Figure 1: Example of Concealed Entrainment from the 
Middle of the VT Isthmus in a Patient with IHD
Threshold for low voltage scar set at 0.30 mV (red), with normal voltage tissue set at 1.0 mV 
(purple). Scar is seen predominantly distributed across the right ventricle. Multiple ablation 
lesions are displayed as grey and red spherical tags. ARVC = arrhythmogenic right ventricular 
cardiomyopathy; LAO = left anterior oblique.
Figure 2: Bipolar Voltage of Epicardial Substrate in Patient 
with ARVC in LAO Projection
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tissue are identified.30,31 Early work employing subendocardial surgical 
resection of these areas eliminated approximately 50 % of the abnormal 
signals and reduced VT recurrence.32 Homogenisation of scars, 
involving ablation of these abnormal potentials within scars, reduces 
VT recurrence in patients with ischaemic cardiomyopathy.21 Translation 
of these results to non-ischaemic cardiomyopathy is difficult, with 
outcome measures less impressive than with ischaemic cohorts.22 The 
extensive ablation of late potentials in a patient with arrhythmogenic 
right ventricular cardiomyopathy is illustrated in Figure 2.
Extensive ablation of local abnormal ventricular activities has also been 
demonstrated to significantly reduce VT recurrences in secondary 
prevention cases, but extensive ablation is required with long procedure 
times of up to 186 +/–78 minutes. This highlights the question of how 
much ablation is truly required to prevent recurrences.33 As such, 
there is no universal agreement on optimal ablation strategy for scar 
substrate. Randomised trials examining substrate-based ablation exist 
in the form of the ablation of clinical ventricular tachycardia versus 
addition of substrate ablation on the long term success rate of VT 
ablation (VISTA) and the substrate mapping and ablation in sinus 
rhythm to halt ventricular tachycardia (SMASH-VT) trials. The VISTA 
trial demonstrated that an extensive substrate-based approach was 
superior to a more focused activation mapping strategy. For obvious 
reasons, only tolerated VT was included in the activation mapping arm, 
and whether these results can be extrapolated to the wider VT cohort of 
patients is unclear.34 The randomised, primary-prevention trial, SMASH 
VT, showed a reduction in VT events using a substrate-based approach.35 
The positive results of this trial, which achieved a 70  % reduction 
in arrhythmic events at 2 years, has not been replicated.
There are many reasons that could explain why the results have 
been disappointing. Voltage mapping using standard parameters of 
>1.5 mV as normal tissue and <0.5 mV as scar tissue might lead to 
underestimation of the heterogeneity of the tissue mapped.36 The 
use of bipolar voltage to locate islands of surviving myocardium 
that could form conducting channels supporting VT is limited by the 
current technologies employed, primarily 3.5-mm bipolar ablation 
catheters. Using smaller electrode sizes with closer bipolar spacing to 
minimise far-field potentials can increase resolution, and has been to 
shown delineate areas of surviving myocardium that were labelled 
as inert scars on maps produced with larger electrodes (e.g., using 
multipolar PentaRay and duodecapolar catheters).37–39 Electrode 
spacing is not the only potential source of error when attempting to 
delineate scars. The angle at which the catheter is placed on the muscle 
can lead to falsely low bipolar voltage if it too steep, as the electrodes 
are activated simultaneously and signal cancellation occurs.40
Wavefront direction is another source of error, with late potentials 
present during apical pacing disappearing during ectopic beats.36 This 
phenomenon is also seen when comparing maps created during sinus 
rhythm and during right ventricle pacing. Sinus rhythm maps show 
larger scar areas with fewer late potentials.41 Similarly, differential 
pacing sites during mapping impact voltage maps created. With the 
characterisation of scars being different, especially in septal locations 
and areas of low density, the sensitivity of voltage maps could be 
improved by using separate pacing locations during mapping.42 
Furthermore, isthmuses present during VT might be absent when 
mapping in sinus rhythm. The concept of block being functional 
rather than anatomical has been shown in computer models of VT 
and in clinical studies.43,44 In essence, dynamic changes in conduction-
repolarisation lead to transient lines of block, which are cycle-length 
dependent, creating the opportunity of re-entry to develop at a site. 
Mechanistically, tissue susceptibility to re-entry depends on the 
spatial interaction between refractoriness and conduction dynamics, 
as re-entry requires that a wavefront of excitation finds electrically-
excitable tissue always ahead of it. Favourable conditions for re-entry 
might be met when conduction velocity is slowed by a premature beat 
and where short repolarisation allows the tissue to regain excitability, 
therefore potentially enabling the establishment of a re-entrant 
circuit.45 A metric to quantify tissue susceptibility to re-entry and 
predict critical sites for VT initiation based on this principle has recently 
been proposed.46
Localising a VT exit site is often attempted during ablation using the 
12-lead electrocardiogram (ECG). These sites can be paced during 
sinus rhythm and compared morphologically to 12-lead ECGs, with 
most modern mapping systems containing software to produce a 
degree of match between the two. Due to the prevalence of ICDs in 
the patient cohort, a 12-lead ECG of the clinical VT is rarely captured, 
and the cycle length of the tachycardia stored on an ICD is often used 
to identify whether an induced VT is likely to be clinical. Despite the 
lack of a preprocedural ECG, VT induced during the case can be used 
to guide the operator to potential areas of interest. In idiopathic VT, 
the 12-lead ECG can localise anatomical regions where a VT exit site 
is most likely to be present. While similar algorithms have been used 
with some success in patients with structurally-abnormal hearts,47 the 
applicability of facets of these algorithms is questionable. In an invasive 
non-contact mapping study, the use of concordance in the precordial 
leads was not found to be useful in infarct-related VT.48 Furthermore, 
algorithms to assess for epicardial exit sites, which would be useful 
in preprocedural planning, have proved inaccurate.49 Pacing in sinus 
rhythm from sites of concealed entrainment produces unmatched 
pace maps in just under one-third of cases.50 Proposed mechanisms 
underlying the limitations of pace mapping include differential areas 
of block present during sinus rhythm and VT resulting in different 
QRS morphologies, and different pacing outputs resulting in divergent 
myocardial capture.51 Despite these issues, the utilisation of pace 
mapping to locate, and subsequently ablate, scar areas with multiple 
exit sites has been shown to improve VT-free survival in a single-centre 
study;52 the implication being the potential to deliver more targeted 
ablation lesions in regions more likely to support VT.
Epicardial Access
Studies investigating non-ischaemic cardiomyopathy have 
demonstrated a greater proportion of potentially-arrhythmogenic 
substrate in the epicardium compared to the endocardium.53,54 These 
studies utilised percutaneous epicardial access for mapping, with 
this technique first described in patients with Chagas disease.55 Cano 
et al. found that epicardial low-voltage areas were more prevalent 
and larger in the epicardium compared to the endocardium in non-
ischaemic cardiomyopathy.54 In ischaemic cardiomyopathy, its utility 
is less convincing, with an endocardial predilection for scars in 
these cohorts. However, when initial endocardial ablation has failed, 
a combined approach in redo procedures might produce positive 
results.56 Damage to subdiaphragmatic organs during puncture can 
occur, and haemorrhage from diaphragmatic vessels has been 
reported. Pericardial effusion is common; it occurs due to damage 
caused to the myocardium by ablation and puncture of the right 
ventricle or coronary arteries. The latter of these also needs to 
be considered during ablation, with imaging utilised to ensure 
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ablation is remote from the arteries.57 Despite these potential risks, 
it has proved to be a safe procedure with low complication rates.58 
In summary, although current practice varies in different centres, 
an epicardial approach is usually performed when there has been a 
failed endocardial approach or the underlying substrate is likely to be 
epicardial. The latter is delineated based on aetiology and potentially 
preoperative scar imaging.59
Complications
Major complications occur in approximately 8–10  % of VT ablation 
procedures,60 with lower mortality. The three main complications are 
vascular injury, stroke and cardiac tamponade. In a large, single-centre 
study of both idiopathic VT and structurally-abnormal heart VT, access-
site vascular injury was the most frequent complication at 3.6 %, with 
stroke and tamponade both <1 %.61 No procedural deaths occurred 
in this study. The incidence of vascular complication might be higher 
in ischaemic heart disease cohorts, and although the incidence 
of stroke is low, the use of irrigated catheters is also purported to 
reduce the risk of stroke further by preventing coagulum formation 
on catheter tips.62 Complications can perhaps be further minimised 
with the use of a lower-power output of 30–40 watts during ablation.61 
Anticoagulation during ablation is achieved with intravenous heparin, 
and post-ablation anticoagulation is recommended for 6–12 weeks 
with either aspirin or warfarin.63
Endpoints for VT Ablation
Traditional focus is on the labelling of clinical and non-clinical VTs 
occurring during ablation. Clinical VT being denoted as such if it is 
similar to the 12-lead ECG, the cycle length recorded from an ICD 
or occurs spontaneously during mapping. However, arrhythmias 
labelled as non-clinical might in fact occur spontaneously in the 
out-of-hospital setting.12 Studies have differed in their approaches 
to these distinct re-entrant circuits. Using programmed electrical 
stimulation at the end of a procedure, some focus only on the clinical 
VT and others have included non-clinical VTs for their non-inducibility 
endpoints. Guideline consensus states that non-inducibility of clinical 
VT in response to programmed electrical stimulation should be 
considered the minimum endpoint after ablation.63 Della Bella et al. 
found that non-inducibility of all VTs was associated with significantly 
lower cardiac mortality.64 Others have shown inducibility of non-
clinical VT to be associated with recurrence.65,66 In contrast, a recent 
pooled analysis of studies showed that non-inducibility of VT was 
not associated with lower recurrence.67 With no available studies 
specifically designed to address the question of optimal endpoints, it 
is difficult to produce standardised outcome measures.
The recent increased use of substrate homogenisation necessitates 
a standardised method for assessing whether all targeted late 
potentials have been successfully ablated.59 Scar remapping is 
one suggested method of assessment, and with more expedient 
mapping, technologies might become more commonplace.68 Lack of 
capture with high-output pacing has been used in addition to late 
potential abolition as an endpoint. This has been employed particularly 
when late potentials are still recorded, despite extensive delivery of 
radiofrequency energy.21
Future Directions
Cardiac MRI Delineation of Scar and Pro-Arrhythmic 
Circuits
Cardiac MR imaging of scars shows promise as an adjunct to traditional 
electrophysiologically-based mapping. Gadolinium late enhancement 
demarcates extracellular space and is a well-validated surrogate 
marker of dense fibrosis. It can delineate heterogeneous tissue within 
scars that could form the isthmus of a re-entrant circuit.69
Despite the potential utility of cardiac MRI to identify potential ablation 
targets, its use remains limited. The main problem being the artefact 
caused by ICD generators and leads in many VT patients. A novel 
wideband technique enables optimised scar evaluation in patients 
with ICDs without any adverse sequelae (Figure 3). The acquired pixel 
Area of earliest activation can be seen in red in the inferior basal region, with the wavefront 
path highlighted by the curved arrow. Entire cycle length is localised to a single pivot point, 
suggestive of discrete local re-entry with an adjacent site of early activation; this would need 
to be fully confirmed with additional point collection and entrainment at the pivot site. Used 
with permission from Boston Scientific. VT = ventricular tachycardia.
Figure 3: Wideband Cardiac MRI Showing Inferolateral 
Scar (left). Image on the Right is Prior to Application of 
Wideband Technology to Remove the Artefact Caused by 
the ICD Generator
Courtesy of Dr Charlotte Manistay, Barts Heart Centre. ICD = implantable cardiac defibrillator.
Figure 4: Orion Basket Catheter Used with the  
RHYTHMIA System, Containing 64×0.4 mm2 Electrodes  
with 2.5 mm Centre-to-centre Spacing to Enable  
Higher-resolution Mapping
Figure 5: High-resolution Mapping of Sustained 
Monomorphic VT (right) and Electrograms from the Roving 
Catheter (left)
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spatial resolution of cardiac MRI using wide-band late enhancement 
at our centre is fixed by the sequence parameters at 1.4×1.4×4 mm 
(contiguous segmented 4-mm slices throughout the ventricles). This 
represents a sample of 8 µg of myocardium using non-interpolated 
data. It compares favourably to previously-published data for scar 
imaging by MRI, and is similar to resolution of voltage maps in vivo 
(3–5 mm). Crucially, MRI-derived scar analysis can also determine scar 
transmurality with distance from endo/epicardial borders. A transmural 
scar of >75  % corresponds to areas of slow conduction, known to 
be a necessary component for a re-entrant circuit, and scars >25  % 
of left ventricle wall thickness is necessary for critical sites involved in 
the maintenance of VT.70 Recent work has highlighted the capacity of 
navigator-gated inversion recovery 3D sequencing to correctly identify 
conducting channels when compared to electro-anatomical maps. 
The technique correlates well with electro-anatomical maps, and no 
significant deviation is seen in lead parameters.71 The availability of 
the integration of MRI scar and channel maps into available electro-
anatomical mapping software could provide valuable information to 
electrophysiologists during catheter ablation. More studies need to be 
conducted to evaluate both the validity and efficacy of this approach. 
This is especially relevant when one considers the resolution of cardiac 
MRI relative to that of contact mapping catheters and the size of the 
channels in question, which might be only be <1 mm in diameter. 
Cardiac MRI using 1.5 tesla magnets has a resolution of 4 mm, 
whereas 2-mm (1-mm spacing), high-density EP catheters, which take 
into account stability and electrode density, can resolve up to 2 mm 
of tissue and recognise very low amplitude signals in diffuse scars 
beyond the resolution of gadolinium.72 This is because gadolinium 
uptake is measured relative to ‘normal’ segments, and thus could miss 
diffuse fibrosis akin to balanced ischaemia being reported as ‘normal 
perfusion’ on nuclear imaging.
Multielectrode High-Resolution Mapping
The limitations of current mapping systems have demanded the 
development of new technologies that achieve higher temporal and 
spatial resolution. This is made possible by using smaller electrodes with 
closer spacing, automated software allowing rapid data collection and 
accurate time annotation of electrograms with multiple components. 
The RHYTHMIA high-density mapping system, utilising a 64-electrode, 
high-density mapping Orion basket catheter, has led to important 
insights into the mechanisms of VT (Figures 4 & 5). A porcine study 
confirmed that in mapped sustained VT, portions of block in a re-entrant 
circuit was functional rather than anatomical.73 This finding confirms 
previous work stated above72, and has been confirmed in a further study.
Entrainment mapping was also employed in this study, and areas where 
criteria for entrainment were met were associated sites distinct from 
the re-entrant circuit. The length of isthmuses was also overestimated 
by entrainment.73 Although allowing for faster mapping, this system does 
not solve the problem posed by haemodynamically-unstable rhythms, 
as sequential mapping in tachycardia is still required. It could however 
improve outcomes in tolerated VT. With regards to substrate mapping, 
the RHYTHMIA system, in conjunction with a basket, shows better 
correlation with MRI scar maps than standard catheter mapping.74
Reported human studies are thus far limited, with most studies 
examining the atrial substrate. In one series, the system was able to 
successfully map 24 of 28 atrial tachycardias that were incompletely 
mapped during the prior procedures employing standard techniques, 
and 22 were successfully terminated.75 The safety and efficacy of the 
procedure in ventricular arrhythmia have been reported in one study. 
Findings were positive, showing no complications, consistent recording 
of abnormal electrograms and good medium-term outcomes for 
freedom from VT.76
Other technologies, such as ripple mapping, might also help solve 
problems posed by current mapping techniques. The system displays 
electrogram components as a dynamic bar that protrudes from 
standard geometry. It has been shown to correctly identify conducting 
channels in scarred myocardium, and has been used in VT ablation 
with successful preliminary results.77,78 These newer mapping systems 
could be further integrated in future with technologies, such as 
intracardiac echocardiography, to allow improved visualisation of 
ventricular anatomy.79 Additionally, this technology has been shown 
to accurately identify wall motion abnormalities and corresponding 
scars,80 thus potentially aiding in the localisation of the arrhythmogenic 
substrate, and can aid ablation in regions of the heart that are 
troublesome to target.81
Electrocardiographic Imaging
The global changes in electrophysiological parameters over both 
ventricles are not easily accessible using conventional sequential 
mapping techniques, and thus information is lost. This is especially 
critical to modelling approaches attempting to predict arrhythmia, 
which then have to rely on structural surrogates, such as gadolinium 
uptake and diffusion on MRI, to estimate conductivity parameters 
as opposed to global electrophysiological data. The ECG Imaging 
(ECG-I) system, developed by Yoram Rudy, utilises inverse solution 
mathematics to generate a unipolar electrogram map derived from 
high-density surface ECG jacket recording, which is projected onto the 
patient’s CT-derived cardiac geometry. It has been validated in canine 
models, patients undergoing cardiac surgery and ablation of focal 
ventricular ectopy.82–89
ECG-I has the potential to map arrhythmias using a single cardiac 
cycle, and thus could be relevant in the mapping of unstable VT 
(Figure 6). When assessing ECG-I data in patients with prior MI, 
a good correlation between scars on MRI and low-amplitude virtual 
electrograms was demonstrated. Fractionated potentials also had 
good correlation with sites of fibrosis on MRI, albeit less so than for 
low-amplitude electrograms. This feature could be attributable to the 
false identification of epicardial fat as scars on MRI. Late potentials 
can also be seen within scarred myocardium. During sinus rhythm 
mapping, these scarred areas alter the activation wavefront and form 
areas of conduction block. This information could be used to limit 
Electrogram (arrow) shows a Q wave indicative of the epicardial site of earliest activation 
corresponding to scar border zone site marked ‘X’. Endocardial bipolar voltage maps from 
this patient showed no scar. ECG-I = electrocardiographic imaging.
Figure 6: Posterior–anterior View of Epicardial Bipolar 
Voltage Map (left) Showing Extensive Epicardial Scar. 
Posterior–anterior View of ECG–I Map (CardioInsight system, 
Medtronic) Showing Site of Earliest Activation (Earliest 
White) of Ventricular Tachycardia in the Same Patient
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ablation to specific pre-identified regions when a substrate-mapping 
approach is employed.90
The system has also studied post-MI VT. Activation time was used to map 
the re-entrant circuits, which were correctly mapped to areas of scar. 
Predictions of site of onset were accurate for distinguishing between 
epicardial, intramural and endocardial locations utilising electrogram 
morphology; that is, pure Q waves representing true epicardial sites. This 
latter point highlights an important facet for clinical use. The prediction of 
the necessity of epicardial access could significantly shorten procedure 
times and enable a more focused ablation strategy.91 Additionally, given 
that many VTs cannot be sequentially mapped, knowledge of the exit site 
would be invaluable for the clinician during ablation. Current validation 
studies show an accuracy for mapping the site of origin of 4–6 mm.92 This 
degree of resolution might not be sufficient to guide ablation, but could 
enable expedited pace mapping of exit sites. Whether these potential 
applications would improve outcomes need to be tested in large trials, 
although procedure planning, workflow and catheter laboratory time 
might be reduced.
Conclusions
Advances in high-density and non-invasive mapping technologies are 
enabling far more detailed interrogation of myocardial substrates than 
previously possible, coupled with major technological developments 
in imaging. This means that we can now study potential circuits and 
plan procedures in a more informed manner.93 The key challenges 
of mapping unstable VTs remain to be fully addressed, as well as 
optimising substrate-based approaches to enable more targeted, 
less extensive ablation, if this is possible. This will require deeper 
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